Rheumatology ·
Lupus Foundation highlights diagnostic, care-access and research findings at ACR
The Lupus Foundation of America previewed studies and presentations scheduled for ACR Convergence 2026, including a Phase II trial of mesenchymal stromal cells and registry analyses involving thousands of people with lupus. The findings address treatment response, diagnostic delays, specialty-care access and patient priorities; most are conference abstracts, with limited methodological detail in the announcement.
- Phase II MSC trial reported responses in nearly half of participants.
- Registry data from 3,063 people examined diagnostic delays.
- Claims analysis found 36% were not receiving medication from a rheumatologist.
- Further details and full trial results were not included.
The Lupus Foundation of America (LFA) announced research presentations planned for the American College of Rheumatology Convergence 2026 meeting in Orlando. The program includes an LFA-funded, multicenter, double-blind, placebo-controlled Phase II trial of mesenchymal stromal cells (MSCs) in refractory lupus, as well as analyses of registry and claims data. The announcement does not provide the trial’s sample size, response definition, or full results.
LFA reports that a single high-dose MSC infusion produced treatment responses in nearly half of trial participants, more than twice the placebo rate. The Foundation says the findings support further evaluation in a confirmatory trial. Separately, an analysis of participant-reported registry data from 3,063 people with systemic lupus erythematosus (SLE) identified demographic factors and symptoms associated with different diagnostic timelines. A nationwide claims analysis found that 36% of identified participants were not receiving lupus medication from a rheumatologist. Another registry analysis of 4,771 people reported differences in symptoms, treatment priorities and desired outcomes across race and ethnicity.
These findings may help identify research and care gaps, but the announcement provides few details on methods, effect estimates or potential confounding. The MSC results are preliminary Phase II findings reported by the Foundation; they do not establish efficacy or support a change in treatment. Other work is described as conference research, and should be interpreted in light of the underlying study designs and full abstracts.
In practice
The announcement describes a Phase II trial in refractory lupus in which the LFA reports responses after a single high-dose MSC infusion in nearly half of participants, compared with less than half that rate on placebo. This is preliminary evidence: the release gives no sample size, response definition, safety results or statistical estimates, and says a confirmatory trial is needed. It does not establish MSCs as an effective treatment or justify changing current care. The registry and claims findings identify potential diagnostic and specialty-care gaps but do not establish their causes.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
PR Newswire – Health: Lupus Foundation of America Showcases New Research Advancing Lupus Diagnosis and Care at American College of Rheumatology Convergence 2026 ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.